ADAPTHEALTH CORP.

ADAPTHEALTH CORP. ANNOUNCES THIRD

QUARTER 2020 FINANCIAL RESULTS

Plymouth Meeting, PA - November 4, 2020 - AdaptHealth

Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a leading provider of home healthcare equipment,

medical supplies to the home and related services in the United States, announced today

financial results for the three- and nine-month periods ended September 30, 2020.

Third Quarter Results

While it is difficult to predict the duration of the COVID-19

crisis, based on current business and market trends, the Company is increasing financial guidance for fiscal year 2020 for net

revenue to $1.00 billion to $1.04 billion, Adjusted EBITDA to $186 million to $194 million, and Adjusted EBITDA less Patient Equipment

Capex to $124 million to $130 million.

For 2021, the Company is guiding net revenue of $1.30 billion

to $1.40 billion, Adjusted EBITDA of $260 million to $280 million and Adjusted EBITDA less Patient Equipment Capex of $180 million

Luke McGee, Chief Executive Officer

of AdaptHealth, commented, "Our strong year-to-date financial performance and improved outlook for the remainder of 2020

reflects the tremendous efforts of our employees and their dedication to our patients and healthcare partners. We have remained

opportunistic throughout the quarter, acquiring several diabetes management and home medical equipment businesses in high-growth

areas. Additionally, on October 1, 2020, we acquired Pinnacle Medical Solutions, a leading distributor of medical devices and

supplies to patients for the treatment of diabetes, including continuous glucose monitors and insulin pumps.

"I am very proud of the dedication, courage, and professionalism

of our employees as they continue to serve our patients and referral partners throughout this crisis, while also continuing to

remain focused on delivering record financial results and establishing a strong foundation for 2021."

Management will host a conference at 8:30

am ET today to discuss the results and business activities. Interested parties may participate in the call by dialing:

Webcast registration: Click Here

Following the live call, a replay will be available for six

months on the Company's website, www.adapthealth.com under "Investor Relations."

About AdaptHealth Corp.

AdaptHealth is a leading provider of home healthcare equipment,

medical supplies to the home and related services in the United States. AdaptHealth provides a full suite of medical products

and solutions designed to help patients manage chronic conditions in the home, adapt to life and thrive. Product and services

offerings include (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals

suffering from obstructive sleep apnea, (ii) medical devices and supplies to patients for the treatment of diabetes (including

continuous glucose monitors and insulin pumps), (iii) home medical equipment (HME) to patients discharged from acute care and

other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME medical devices and supplies

on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company

is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep

labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial

insurance payors. AdaptHealth services approximately 1.8 million patients annually in all 50 states through its network of 269

locations in 41 states. Learn more at www.adapthealth.com.

Forward-Looking Statements

This press release includes certain statements that are not

historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private

Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe,"

"may," "will," "estimate," "continue," "anticipate," "intend,"

"expect," "should," "would," "plan," "predict," "potential,"

"seem," "seek," "future," "outlook," and similar expressions that predict or indicate

future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not

limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and

projections of market opportunity and expectations and the Company's acquisition pipeline. These statements are based on

various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These

forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied

on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events

and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances

are beyond the control of the Company.

These forward-looking statements are subject to a number of

risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party

or governmental investigations to which the Company may become subject that could interrupt or limit the Company's operations,

result in adverse judgments, settlements or fines and create negative publicity; changes in the Company's clients'

preferences, prospects and the competitive conditions prevailing in the healthcare sector; and the impact of the recent coronavirus

(COVID-19) pandemic and the Company's response to it. A further description of such risks and uncertainties can be found

in the Company's filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect,

actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks

that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to

differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's

expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that

subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect

to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do

so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date

subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Use of Non-GAAP Financial Information and Financial Guidance

This release contains non-GAAP financial guidance, which is

adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis.

These non-GAAP items are adjusted after considering their quantitative and qualitative aspects and typically have one or more

of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results

of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods

and will likely reoccur in future periods.

The Company uses EBITDA, Adjusted EBITDA and Adjusted EBITDA

less Patient Equipment Capex, which are financial measures that are not prepared in accordance with generally accepted accounting

principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors,

as a supplement to U.S. GAAP measures. In addition, the Company's ability to incur additional indebtedness and make investments

under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA

less Patient Equipment Capex.

The Company believes Adjusted EBITDA less Patient Equipment

Capex is useful to investors in evaluating the Company's financial performance. The Company's business requires significant

investment in equipment purchases to maintain its patient equipment inventory. Some equipment title transfers to patients'

ownership after a prescribed number of fixed monthly payments. Equipment that does not transfer wears out or oftentimes is not

recovered after a patient's use of the equipment terminates. The Company uses this metric as the profitability measure in

its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most

often used for purposes of contingent consideration arrangements. In addition, the Company's debt agreements contain covenants

that use a variation of Adjusted EBITDA less Patient Equipment Capex for purposes of determining debt covenant compliance. For

purposes of this metric, patient equipment capital expenditure is measured as the value of the patient equipment received during

the accounting period without regard to whether the equipment is purchased or financed through lease transactions.

EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment

Capex should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA, Adjusted

EBITDA and Adjusted EBITDA less Patient Equipment Capex are significant components in understanding and assessing financial performance.

Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative

to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating

activities as a measure of the Company's liquidity.

There is no reliable or reasonably estimable comparable GAAP